Cargando…

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy

SIMPLE SUMMARY: While the development of immunotherapy has greatly advanced cancer treatment, many patients do not benefit from immunotherapy. Numerous strategies have been developed to improve response to immunotherapy across cancer types, including blocking the activity of immunosuppressive immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bullock, Kennady, Richmond, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699249/ https://www.ncbi.nlm.nih.gov/pubmed/34944914 http://dx.doi.org/10.3390/cancers13246293

Ejemplares similares

Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis
por: Li, Yichen, et al.
Publicado: (2022)

Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment
por: Rashid, Mohammad H., et al.
Publicado: (2021)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
por: Mezzapelle, Rosanna, et al.
Publicado: (2022)

Cancer-Derived VEGF-C Increases Chemokine Production in Lymphatic Endothelial Cells to Promote CXCR2-Dependent Cancer Invasion and MDSC Recruitment
por: Chen, Jing-Yi, et al.
Publicado: (2019)

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
por: Han, Zhi-Jian, et al.
Publicado: (2021)

Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
por: Zilio, Serena, et al.
Publicado: (2016)

Spleen-Derived CCL9 Recruits MDSC to Facilitate Tumor Growth in Orthotopic Hepatoma Mice
por: Li, Baohua, et al.
Publicado: (2023)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
por: Ghonim, Mohamed A, et al.
Publicado: (2021)

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy
por: Li, Zhaoting, et al.
Publicado: (2020)

Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer
Publicado: (2021)

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy
por: Raber, Patrick L., et al.
Publicado: (2016)

Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
por: Ohl, Kim, et al.
Publicado: (2018)

LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
por: Chai, ErQing, et al.
Publicado: (2019)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3
por: Han, Xiaoqing, et al.
Publicado: (2019)

CXCR1/CXCR2 Antagonism Is Effective in Pulmonary Defense against Klebsiella pneumoniae Infection
por: Wei, Jing, et al.
Publicado: (2013)

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
por: Metzger, Philipp, et al.
Publicado: (2020)

Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts
por: Raber, Patrick L, et al.
Publicado: (2013)

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
por: Li, Tianhang, et al.
Publicado: (2021)

Correction: CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3
por: Han, Xiaoqing, et al.
Publicado: (2019)

Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
por: Zhang, Chenyu, et al.
Publicado: (2019)

CXCR4 Antagonism to Treat Delayed Fracture Healing
por: Meeson, Richard, et al.
Publicado: (2019)

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2–DOP receptor heterodimer
por: Parenty, Geraldine, et al.
Publicado: (2008)

The immune suppressive microenvironment affects efficacy of radio‐immunotherapy in brain metastasis
por: Niesel, Katja, et al.
Publicado: (2021)

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer
por: Wang, Zibing, et al.
Publicado: (2015)

Targeting YAP-dependent MDSC infiltration impairs tumor progression
por: Wang, Guocan, et al.
Publicado: (2015)

The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis
por: Hawkins, Oriana E, et al.
Publicado: (2012)

Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
por: Ghosh, Chandra C., et al.
Publicado: (2022)

A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia
por: Kong, Fei, et al.
Publicado: (2022)

New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy
por: Guo, Gang, et al.
Publicado: (2015)

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
por: Devaud, Christel, et al.
Publicado: (2013)

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
por: Peng, Shaojun, et al.
Publicado: (2021)

CXCR3: Here to stay to enhance cancer immunotherapy?
por: Rogava, Meri, et al.
Publicado: (2019)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
por: Wang, Qianqian, et al.
Publicado: (2023)

CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis
por: Chu, Po-Yin, et al.
Publicado: (2015)

CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis
por: Pouzol, Laetitia, et al.
Publicado: (2021)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition
por: Wang, Yungang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8puapflr7q23d8vhgqevikjem7